AbbVie, InterMune Sue EMA on Data Confidentiality
Wednesday, March 13, 2013
AbbVie Inc. and InterMune Inc. could derail the European Medicines Agency's (EMA) carefully timetabled introduction of a new data transparency regime on Jan. 1, 2014, by seeking court injunctions preventing the disclosure of clinical trial data for their respective principal products, Humira (adalimumab) and Esbriet (perfidenone).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.